New Drug Halts Pancreatic Tumor Growth

338 Vues· 11/22/26
Picup ENG
Picup ENG
Les abonnés
0

A newly approved drug called daraxonrasib, when combined with standard chemotherapy drugs, has demonstrated significant effectiveness in halting tumor growth in patients with advanced pancreatic cancer, according to clinical trial results presented at a major international cancer conference. The oral medication, administered alongside gemcitabine and nab-paclitaxel, resulted in tumor shrinkage in 60.7% of patients, while 8.2% experienced complete disappearance of their tumors on scans. The study also reported that tumor progression was stopped in 90.2% of trial participants. Experts state that the drug targets a mutation present in the vast majority of pancreatic cancers, interfering with vital growth signals that allow tumors to persist. The findings have been heralded as a major breakthrough for one of the most challenging cancers to treat, with the combination therapy nearly doubling the period of disease control compared to previous outcomes. Daraxonrasib is now undergoing further global trials to evaluate its effectiveness both with and without chemotherapy.

Montre plus

 0 commentaires sort   Trier par